This systematic approach led to a greater disparity in the risks of nausea and nerve damage compared to myocardial infarction and stroke, as nerve damage is common in T2D patients [60], while the risk of nausea is mainly associated with the initial months of GLP-1 use [61]. Here, GLP1R is linked to type 2 diabetes mellitus.